2004
DOI: 10.1016/j.micinf.2004.04.006
|View full text |Cite
|
Sign up to set email alerts
|

Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
45
0
2

Year Published

2006
2006
2018
2018

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(47 citation statements)
references
References 29 publications
0
45
0
2
Order By: Relevance
“…Whole-cell preparations obtained from 48 h static cultures in LB broth were run on SDS-PAGE and proteins were transferred to nitrocellulose membranes (Bio-Rad) as described by Towbin et al (1979). Western immunoblots were performed using a 1 : 200 dilution in PBS/Tween 20/1 % (w/v) skimmed milk of rabbit polyclonal immune sera raised against MrpA (Zunino et al, 2001), PmfA (Zunino et al, 2003) and AtfA (Zunino et al, 2000), and mouse polyclonal immune sera raised against UcaA (Scavone et al, 2004). Isogenic fimbrial mrpA, pmfA, atfA-C and ucaA mutants were included as controls in the Western blotting assays (strains MSD2, P2, A4 and UM1 respectively; see Table 1).…”
Section: Sds-pagementioning
confidence: 99%
“…Whole-cell preparations obtained from 48 h static cultures in LB broth were run on SDS-PAGE and proteins were transferred to nitrocellulose membranes (Bio-Rad) as described by Towbin et al (1979). Western immunoblots were performed using a 1 : 200 dilution in PBS/Tween 20/1 % (w/v) skimmed milk of rabbit polyclonal immune sera raised against MrpA (Zunino et al, 2001), PmfA (Zunino et al, 2003) and AtfA (Zunino et al, 2000), and mouse polyclonal immune sera raised against UcaA (Scavone et al, 2004). Isogenic fimbrial mrpA, pmfA, atfA-C and ucaA mutants were included as controls in the Western blotting assays (strains MSD2, P2, A4 and UM1 respectively; see Table 1).…”
Section: Sds-pagementioning
confidence: 99%
“…They aid in the process of infection by mediating adhesion, aggregation, hemagglutination, or motility in vivo (39). Their use in developing subunit vaccines against P. mirabilis has also been explored (45,46); however, phase variation of certain fimbriae requires that they be used only in conjunction with other proteins as part of a multivalent vaccine (26,59). Thus, identifying nonfimbrial surface proteins that contribute to the pathogen's persistence in vivo is critical.…”
mentioning
confidence: 99%
“…All bacterial suspensions were in PBS. Immunization was performed by instilling 10 ml bacterial suspension into each nostril (Pellegrino et al, 2003;Scavone et al, 2004Scavone et al, , 2009. Vaccination was performed twice on days 1 and 28 (Pickett et al, 2000).…”
Section: Methodsmentioning
confidence: 99%